Evaluation of the Duration of Obtaining Curative Anticoagulation in Patients With Clinically Significant Pulmonary Embolism in an Intensive Care Unit

Last updated: March 28, 2025
Sponsor: University Hospital, Strasbourg, France
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pulmonary Embolism

Chest Pain

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT06912009
9373
  • Ages > 18
  • All Genders

Study Summary

Current management of intermediate- and high-risk pulmonary embolism is primarily based on curative subcutaneous or intravenous anticoagulation, with or without systemic fibrinolytic therapy or thrombectomy (8). Initial treatment with low-molecular-weight heparin (LMWH) or fondaparinux is preferred over unfractionated heparin (UFH) due to their lower risk of serious bleeding and heparin-induced thrombocytopenia (HIT) (9). UFH treatment is reserved for patients at risk of hemodynamic instability, renal failure with a GFR < 30 ml/min, or obesity (8). Biological monitoring of anticoagulation efficacy can be performed by measuring the activated partial thromboplastin time (aPTT), as recommended by the European Society of Cardiology (ESC), or by measuring the antiXa activity of heparin, which has been shown to be beneficial in numerous studies (10,11,12). It is generally accepted that this anticoagulation should be initiated at a curative dose as early as possible (8), as this reduces in-hospital mortality and 30-day mortality (13). However, few studies have examined the impact of the time to achieve effective anticoagulation, and those that have done so have only done so in patients with high-risk pulmonary embolism (14) or have based their anticoagulation monitoring on aPTT and not on antiXa activity (13).

The proposed study aims to evaluate the time to obtain effective anticoagulation and its impact on mortality, thromboembolic recurrence and the occurrence of serious bleeding in patients with clinically significant pulmonary embolism, hospitalized in an intensive care unit as well as the factors that may influence this time. It will also allow to compare the practices of the studied center in terms of initial anticoagulation dose delivered, the initiation or not of a bolus and methods of monitoring anticoagulation with the literature in order to allow an improvement in patient care.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patient (≥18 years old)

  • Hospitalized in the intensive care unit of Hautepierre Hospital (StrasbourgUniversity Hospitals UF 6250) between January 1, 2014, and December 31, 2023

  • With a diagnosis of pulmonary embolism confirmed by a thoracic CT angiogram, athoracoabdominopelvic CT scan, or a lung scan

  • Having received anticoagulation with curative-dose unfractionated heparin

Exclusion

Exclusion Criteria:

  • Subjects who have expressed objection to the reuse of their data for scientificresearch purposes. - Patients diagnosed with pulmonary embolism prior to admissionto the intensive care unit and for whom we cannot precisely determine the start dateof anticoagulation (precision estimated to the nearest hour).

  • Pulmonary embolism not confirmed by contrast imaging (CT angiography)

  • Patients who have not received curative anticoagulation (contraindication)

  • Patients already receiving curative anticoagulation with UFH at the time ofdiagnosis

  • Patients with low-risk pulmonary embolism defined by an sPESI score of 0

  • Subject under court protection, guardianship, or curatorship

Study Design

Total Participants: 100
Study Start date:
November 06, 2024
Estimated Completion Date:
December 06, 2025

Connect with a study center

  • Service de Réanimation Médicale - CHU de Strasbourg - France

    Strasbourg, 67091
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.